Biotech IV Monitor

TLX — Telix Pharmaceuticals Limited

$3.5B market cap · 6 upcoming readouts tracked

Clinical trial readout dates for Telix Pharmaceuticals Limited, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2027.

Next readoutJanuary 2027in ~2 months
Upcoming readouts65 Phase 3
Market cap$3.5B

Upcoming readouts

Phase 3 68Ga-PSMA-11
PCA; Prostate Cancer · NCT07052214
January 2027
Ongoing
Phase 3 177Lu-TLX250
ccRCC; Renal Cell Carcinoma (Kidney Cancer) · NCT07197580
August 2027
Recruiting
Phase 3 177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer · NCT06520345
December 2027
Recruiting
Phase 3 Floretyrosine F 18 ([18F]FET)
Brain Metastasis; Radiation Necrosis · NCT07931261
April 2028
Not Yet Recruiting
Phase 3 TLX-101-Tx + Lomustine
Neoplastic Disease; Glioblastoma · NCT07100730
July 2028
Recruiting
Phase 2 177Lu-TLX250
ccRCC; Renal Cell Carcinoma (Kidney Cancer) · NCT07870746
December 2028
Not Yet Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow TLX, you can start the conversation.
Track TLX in real time
See live implied volatility for TLX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TLX
Contact — questions or corrections about TLX: dukeupt@gmail.com